Carregant...
Miniatura

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/99562

Immunogenicity and immunization costs of adjuvanted versus non-adjuvanted hepatitis B vaccine in chronic kidney disease patients

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Hepatitis B virus (HBV) vaccination is recommended for all susceptible chronic pre-hemodialysis and hemodialysis patients. This study assessed the immunogenicity of HBV vaccines (adjuvanted and non-adjuvanted) in chronic kidney disease patients vaccinated at the Hospital Clinic of Barcelona (Spain) between January 2007 and July 2012. In addition, the costs for the health system were evaluated according to the proportion of vaccine responders after receiving either vaccine. Patients receiving three doses of hepatitis B adjuvanted vaccine were three times more likely to seroconvert than patients immunized with non-adjuvanted vaccines, OR 3.56 (95% CI 1.84-6.85). This resulted in fewer patients requiring a second course of HBV vaccination and fewer outpatient visits, saving more than euro9,500 per 100 patients. The higher immunogenicity of the adjuvanted HBV vaccine would counterbalance the lower costs associated with the non-adjuvanted vaccine.

Matèries (anglès)

Citació

Citació

VILAJELIU, Alba, SEQUERA BUZARQUIS, Victor guillermo, GARCÍA-BASTEIRO, Alberto l., SICURI, Elisa, ALDEA, Marta, VELASCO MUÑOZ, César, BAYAS RODRÍGUEZ, José maría. Immunogenicity and immunization costs of adjuvanted versus
                non-adjuvanted hepatitis B vaccine in chronic kidney disease
                patients. _Human Vaccines & Immunotherapeutics_. 2016. [consulta: 5 de febrer de 2026]. ISSN: 2164-5515. [Disponible a: https://hdl.handle.net/2445/99562]

Exportar metadades

JSON - METS

Compartir registre